---
title: Innovative PDO Monolayer for IBD Research | IntegriGut Screen
description: Explore our groundbreaking PDO monolayer, a human-relevant model for IBD drug discovery. Get our infosheet for insights on gut barrier inflammation
image: https://resources.huborganoids.nl/hubfs/social-media-pdo-monolayer-info-sheet.jpg
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

INFO SHEET

# PDO Monolayer for Inflammatory Bowel Disease (IBD)

![](https://resources.huborganoids.nl/hs-fs/hubfs/assets2023/pdo-monolayer-for-ibd-thumb.png?width=400&name=pdo-monolayer-for-ibd-thumb.png)

Current treatments for inflammatory bowel disease (IBD), such as 5-ASAs and anti-TNFs, aim to restore gut barrier function and promote epithelial healing. However, up to 40% of IBD patients fail to respond to these therapies, highlighting the urgent need for new treatment approaches and therapeutic targets. Traditional preclinical models, including non-primary monocultures and non-human in vivo models, lack the ability to accurately replicate the human intestinal environment, limiting their translational relevance.

## Patient-Derived Organoids (PDO) Monolayer: A Breakthrough in IBD Research

Our patient-derived organoid (PDO) monolayer is an innovative *in vitro* model that closely mimics the *in vivo* human intestine. This model, derived from IBD patients, is structured as a single, polarized layer composed of various intestinal cell types, providing a physiologically relevant platform to study epithelial barrier function and gut inflammation.

PDO monolayers allow comprehensive assessment of both apical and basal sides of the epithelium, offering critical insights into IBD treatment responses and inflammatory challenges.

## IntegriGut Screen: Accelerating IBD Drug Discovery with PDO Monolayers

To meet the increasing demand for fast, reliable, and human-relevant data, we developed **IntegriGut Screen**, a cutting-edge service utilizing PDO monolayers. This system delivers high-quality human data on epithelial barrier integrity, cytotoxicity, and cytokine release, all crucial for IBD drug discovery and development.

**Download Our Infosheet to Learn About:**

- The process of developing PDO monolayers for modelling epithelial barrier damage in IBD.
- An overview of **IntegriGut Efficacy Screen**, including its strategic design, experimental timelines, and available readouts.
- An introduction to **IntegriGut Biobank Screen**, featuring insights from our extensive IBD biobank.

[download now](https://resources.huborganoids.nl/hubfs/HUB-Organoids-IBD-PDO-Monolayer-IntegriGut-Screen-Final.pdf)

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*